VeriStrat (R) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
| Autor: | Hendricus Groen, Julia Grigorieva, Anne-Marie C. Dingemans, Egbert F. Smit, J. Roder, Joline S.W. Lind, H. Roder, Justine L. Kuiper |
|---|---|
| Přispěvatelé: | Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Pulmonary medicine, CCA - Innovative therapy, MUMC+: MA Med Staf Spec Longziekten (9), Pulmonologie, RS: GROW - School for Oncology and Reproduction |
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Male
Oncology Cancer Research Pathology erlotinib Lung Neoplasms Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Epidermal growth factor receptor personalised therapy Erlotinib Hydrochloride biology Prognosis SAA ErbB Receptors PHASE-II Female Erlotinib Veristrat medicine.drug Niacinamide Sorafenib medicine.medical_specialty Bevacizumab CELL LUNG-CANCER BEVACIZUMAB Context (language use) Disease-Free Survival proteomics Internal medicine medicine TYROSINE KINASE INHIBITORS Humans Lung cancer Protein Kinase Inhibitors neoplasms Neoplasm Staging business.industry Phenylurea Compounds MASS-SPECTROMETRY medicine.disease respiratory tract diseases lung cancer Receptors Vascular Endothelial Growth Factor serum biomarker Quinazolines Clinical Study biology.protein PATTERNS sorafenib business GROWTH-FACTOR RECEPTOR |
| Zdroj: | British Jounal of Cancer, 107(11), 1820-1825. Nature Publishing Group British Journal of Cancer, 107(11), 1820-1825. Nature Publishing Group Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C & Smit, E F 2012, ' VeriStrat (R) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib ', British Journal of Cancer, vol. 107, no. 11, pp. 1820-1825 . https://doi.org/10.1038/bjc.2012.470 British Journal of Cancer |
| ISSN: | 0007-0920 |
| DOI: | 10.1038/bjc.2012.470 |
| Popis: | BACKGROUND: The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In this study, VeriStrat was evaluated as a pre-treatment stratification tool in patients with advanced stage NSCLC for treatment with the combination of erlotinib and sorafenib, considering both OS and progression-free survival (PFS) as end points.METHODS: Serum samples from 50 patients treated within the context of a phase II trial of first-line erlotinib and sorafenib were analysed with VeriStrat, a fully locked mass spectrometry-based test that identifies patients likely to have good or poor outcome on EGFR therapy based on eight distinct features in mass spectra. Analysis was performed fully blinded to all clinical data, and then the outcome data were analysed with respect to the obtained serum classifications.RESULTS: VeriStrat classified pre-treatment samples into two groups, VeriStrat Good and VeriStrat Poor, which were significantly different in OS (hazard ratio (HR) 0.30, log-rank P = 0.009) and in PFS (HR 0.40, log-rank P = 0.035).CONCLUSION: VeriStrat has shown its potential for stratification of unselected, advanced stage NSCLC patients treated in first line with a combination of erlotinib and sorafenib. British Journal of Cancer (2012) 107, 1820-1825. doi:10.1038/bjc.2012.470 www.bjcancer.com Published online 18 October 2012 (C) 2012 Cancer Research UK |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|